Evaluation of Circulating Platelet Extracellular Vesicles and Hypertension Mediated Organ Damage
Abstract
:1. Introduction
2. Results
2.1. Platelet Derived Extracellular Vesicles and Macro/Microvascular Organ Damage
2.2. Endothelial Function and Platelet Derived Extracellular Vesicles
2.3. Emotional Status and Platelet Derived Extracellular Vesicles
3. Discussion
4. Materials and Methods
4.1. Subject Population and Study Design
4.2. Blood Pressure Evaluation
4.3. Vascular Density
4.4. Arterial Stiffness Evaluation
4.5. Endothelial Function
4.6. Emotional Status Assessment
4.7. Platelet EV Characterization
4.8. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.; Dominiczak, A.; et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018, 39, 3021–3104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lugo-Gavidia, L.M.; Burger, D.; Matthews, V.B.; Nolde, J.M.; Galindo Kiuchi, M.; Carnagarin, R.; Kannenkeril, D.; Chan, J.; Joyson, A.; Herat, L.Y.; et al. Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation. Hypertension 2021, 77, 1825–1844. [Google Scholar] [CrossRef] [PubMed]
- Lip, G.Y.H. Hypertension and the prothrombotic state. J. Hum. Hypertens. 2000, 14, 687–690. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dielis, A.W.; Smid, M.; Spronk, H.M.; Hamulyak, K.; Kroon, A.A.; ten Cate, H.; de Leeuw, P.W. The prothrombotic paradox of hypertension: Role of the renin-angiotensin and kallikrein-kinin systems. Hypertension 2005, 46, 1236–1242. [Google Scholar] [CrossRef] [Green Version]
- Lugo, L.M.; Ferreiro, J.L. Dual antiplatelet therapy after coronary stent implantation: Individualizing the optimal duration. J Cardiol 2018, 72, 94–104. [Google Scholar] [CrossRef] [Green Version]
- Vaccarino, V.; Badimon, L.; Bremner, J.D.; Cenko, E.; Cubedo, J.; Dorobantu, M.; Duncker, D.J.; Koller, A.; Manfrini, O.; Milicic, D.; et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur. Heart J. 2020, 41, 1687–1696. [Google Scholar] [CrossRef] [Green Version]
- Sinauridze, E.I.; Kireev, D.A.; Popenko, N.Y.; Pichugin, A.V.; Panteleev, M.A.; Krymskaya, O.V.; Ataullakhanov, F.I. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb. Haemost. 2007, 97, 425–434. [Google Scholar]
- Rubin, O.; Canellini, G.; Delobel, J.; Lion, N.; Tissot, J.-D. Red blood cell microparticles: Clinical relevance. Transfus. Med. Hemother. 2012, 39, 342–347. [Google Scholar] [CrossRef] [Green Version]
- Blann, A.; Shantsila, E.; Shantsila, A. Microparticles and arterial disease. Semin. Thromb. Hemost. 2009, 35, 488–496. [Google Scholar] [CrossRef]
- Ridger, V.C.; Boulanger, C.M.; Angelillo-Scherrer, A.; Badimon, L.; Blanc-Brude, O.; Bochaton-Piallat, M.L.; Boilard, E.; Buzas, E.I.; Caporali, A.; Dignat-George, F.; et al. Microvesicles in vascular homeostasis and diseases. Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology. Thromb. Haemost. 2017, 117, 1296–1316. [Google Scholar] [CrossRef]
- Maruhashi, T.; Kajikawa, M.; Kishimoto, S.; Hashimoto, H.; Takaeko, Y.; Yamaji, T.; Harada, T.; Han, Y.; Aibara, Y.; Mohamad Yusoff, F.; et al. Diagnostic Criteria of Flow-Mediated Vasodilation for Normal Endothelial Function and Nitroglycerin-Induced Vasodilation for Normal Vascular Smooth Muscle Function of the Brachial Artery. J. Am. Heart Assoc. 2020, 9, e013915. [Google Scholar] [CrossRef]
- Syvänen, K.; Korhonen, P.; Partanen, A.; Aarnio, P. Endothelial function in a cardiovascular risk population with borderline ankle-brachial index. Vasc. Health Risk Manag. 2011, 7, 97–101. [Google Scholar] [CrossRef] [Green Version]
- Lugo-Gavidia, L.M.; Carnagarin, R.; Burger, D.; Nolde, J.M.; Chan, J.; Robinson, S.; Bosio, E.; Matthews, V.B.; Schlaich, M.P. Circulating platelet-derived extracellular vesicles correlate with night-time blood pressure and vascular organ damage and may represent an integrative biomarker of vascular health. J. Clin. Hypertens. 2022, 24, 738–749. [Google Scholar] [CrossRef]
- Lugo-Gavidia, L.M.; Burger, D.; Nolde, J.M.; Carnagarin, R.; Chan, J.; Bosio, E.; Matthews, V.B.; Schlaich, M.P. Platelet-derived extracellular vesicles correlate with therapy-induced nocturnal blood pressure changes. J. Hypertens. 2022, 40, 2210–2218. [Google Scholar] [CrossRef]
- Lugo-Gavidia, L.M.; Nolde, J.M.; Carnagarin, R.; Burger, D.; Chan, J.; Robinson, S.; Bosio, E.; Matthews, V.B.; Schlaich, M.P. Association of Circulating Platelet Extracellular Vesicles and Pulse Wave Velocity with Cardiovascular Risk Estimation. Int. J. Mol. Sci. 2022, 23, 10524. [Google Scholar] [CrossRef]
- Kim, E.J.; Park, C.G.; Park, J.S.; Suh, S.Y.; Choi, C.U.; Kim, J.W.; Kim, S.H.; Lim, H.E.; Rha, S.W.; Seo, H.S.; et al. Relationship between blood pressure parameters and pulse wave velocity in normotensive and hypertensive subjects: Invasive study. J. Hum. Hypertens. 2007, 21, 141–148. [Google Scholar] [CrossRef] [Green Version]
- O’Rourke, M.F.; Pauca, A.; Jiang, X.J. Pulse wave analysis. Br. J. Clin. Pharmacol. 2001, 51, 507–522. [Google Scholar] [CrossRef]
- Vlachopoulos, C.; Aznaouridis, K.; Stefanadis, C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J. Am. Coll. Cardiol. 2010, 55, 1318–1327. [Google Scholar] [CrossRef] [Green Version]
- Ben-Shlomo, Y.; Spears, M.; Boustred, C.; May, M.; Anderson, S.G.; Benjamin, E.J.; Boutouyrie, P.; Cameron, J.; Chen, C.H.; Cruickshank, J.K.; et al. Aortic pulse wave velocity improves cardiovascular event prediction: An individual participant meta-analysis of prospective observational data from 17,635 subjects. J. Am. Coll. Cardiol. 2014, 63, 636–646. [Google Scholar] [CrossRef]
- Vishram-Nielsen, J.K.K.; Laurent, S.; Nilsson, P.M.; Linneberg, A.; Sehested, T.S.G.; Greve, S.V.; Pareek, M.; Palmieri, L.; Giampaoli, S.; Donfrancesco, C.; et al. Does Estimated Pulse Wave Velocity Add Prognostic Information?: MORGAM Prospective Cohort Project. Hypertension 2020, 75, 1420–1428. [Google Scholar] [CrossRef]
- Wang, J.M.; Su, C.; Wang, Y.; Huang, Y.J.; Yang, Z.; Chen, L.; Wu, F.; Xu, S.Y.; Tao, J. Elevated circulating endothelial microparticles and brachial-ankle pulse wave velocity in well-controlled hypertensive patients. J. Hum. Hypertens. 2009, 23, 307–315. [Google Scholar] [CrossRef] [PubMed]
- Kashani, A.H.; Chen, C.L.; Gahm, J.K.; Zheng, F.; Richter, G.M.; Rosenfeld, P.J.; Shi, Y.; Wang, R.K. Optical coherence tomography angiography: A comprehensive review of current methods and clinical applications. Prog. Retin. Eye Res. 2017, 60, 66–100. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.M.; Lee, W.H.; Kim, K.N.; Jo, Y.J.; Kim, J.Y. Changes in thickness of central macula and retinal nerve fibre layer in severe hypertensive retinopathy: A 1-year longitudinal study. Acta Ophthalmol. 2018, 96, e386–e392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, W.H.; Park, J.H.; Won, Y.; Lee, M.W.; Shin, Y.I.; Jo, Y.J.; Kim, J.Y. Retinal Microvascular Change in Hypertension as measured by Optical Coherence Tomography Angiography. Sci. Rep. 2019, 9, 156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muraoka, Y.; Tsujikawa, A.; Kumagai, K.; Akiba, M.; Ogino, K.; Murakami, T.; Akagi-Kurashige, Y.; Miyamoto, K.; Yoshimura, N. Age- and hypertension-dependent changes in retinal vessel diameter and wall thickness: An optical coherence tomography study. Am. J. Ophthalmol. 2013, 156, 706–714. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nolde, J.M.; Frost, S.; Kannenkeril, D.; Lugo-Gavidia, L.M.; Chan, J.; Joyson, A.; Azzam, O.; Carnagarin, R.; Kiuchi, M.G.; Vignarajan, J.; et al. Capillary vascular density in the retina of hypertensive patients is associated with a non-dipping pattern independent of mean ambulatory blood pressure. J. Hypertens. 2021, 39, 1826–1834. [Google Scholar] [CrossRef]
- Alexander, Y.; Osto, E.; Schmidt-Trucksäss, A.; Shechter, M.; Trifunovic, D.; Duncker, D.J.; Aboyans, V.; Bäck, M.; Badimon, L.; Cosentino, F.; et al. Endothelial function in cardiovascular medicine: A consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. Cardiovasc Res 2021, 117, 29–42. [Google Scholar] [CrossRef] [Green Version]
- Barthelmes, J.; Nägele, M.P.; Ludovici, V.; Ruschitzka, F.; Sudano, I.; Flammer, A.J. Endothelial dysfunction in cardiovascular disease and Flammer syndrome-similarities and differences. EPMA J. 2017, 8, 99–109. [Google Scholar] [CrossRef] [Green Version]
- Deanfield, J.E.; Halcox, J.P.; Rabelink, T.J. Endothelial function and dysfunction: Testing and clinical relevance. Circulation 2007, 115, 1285–1295. [Google Scholar] [CrossRef]
- Hadi, H.A.R.; Carr, C.S.; Al Suwaidi, J. Endothelial dysfunction: Cardiovascular risk factors, therapy, and outcome. Vasc. Health Risk Manag. 2005, 1, 183–198. [Google Scholar]
- Versari, D.; Daghini, E.; Virdis, A.; Ghiadoni, L.; Taddei, S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009, 32 (Suppl. S2), S314–S321. [Google Scholar] [CrossRef] [Green Version]
- Panza, J.A.; Quyyumi, A.A.; Brush, J.E., Jr.; Epstein, S.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. 1990, 323, 22–27. [Google Scholar] [CrossRef]
- Juonala, M.; Viikari, J.S.; Rönnemaa, T.; Helenius, H.; Taittonen, L.; Raitakari, O.T. Elevated blood pressure in adolescent boys predicts endothelial dysfunction: The cardiovascular risk in young Finns study. Hypertension 2006, 48, 424–430. [Google Scholar] [CrossRef]
- Perticone, F.; Ceravolo, R.; Pujia, A.; Ventura, G.; Iacopino, S.; Scozzafava, A.; Ferraro, A.; Chello, M.; Mastroroberto, P.; Verdecchia, P.; et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001, 104, 191–196. [Google Scholar] [CrossRef] [Green Version]
- Shimbo, D.; Muntner, P.; Mann, D.; Viera, A.J.; Homma, S.; Polak, J.F.; Barr, R.G.; Herrington, D.; Shea, S. Endothelial dysfunction and the risk of hypertension: The multi-ethnic study of atherosclerosis. Hypertension 2010, 55, 1210–1216. [Google Scholar] [CrossRef] [Green Version]
- Sansone, R.; Baaken, M.; Horn, P.; Schuler, D.; Westenfeld, R.; Amabile, N.; Kelm, M.; Heiss, C. Release of endothelial microparticles in patients with arterial hypertension, hypertensive emergencies and catheter-related injury. Atherosclerosis 2018, 273, 67–74. [Google Scholar] [CrossRef]
- Horn, P.; Stern, D.; Veulemans, V.; Heiss, C.; Zeus, T.; Merx, M.W.; Kelm, M.; Westenfeld, R. Improved endothelial function and decreased levels of endothelium-derived microparticles after transcatheter aortic valve implantation. EuroIntervention 2015, 10, 1456–1463. [Google Scholar] [CrossRef]
- Celano, C.M.; Daunis, D.J.; Lokko, H.N.; Campbell, K.A.; Huffman, J.C. Anxiety Disorders and Cardiovascular Disease. Curr. Psychiatry Rep. 2016, 18, 101. [Google Scholar] [CrossRef] [Green Version]
- Savoy, C.; Van Lieshout, R.J.; Steiner, M. Is plasminogen activator inhibitor-1 a physiological bottleneck bridging major depressive disorder and cardiovascular disease? Acta Physiol. 2017, 219, 715–727. [Google Scholar] [CrossRef]
- Lahlou-Laforet, K.; Alhenc-Gelas, M.; Pornin, M.; Bydlowski, S.; Seigneur, E.; Benetos, A.; Kierzin, J.M.; Scarabin, P.Y.; Ducimetiere, P.; Aiach, M.; et al. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease. Am. J. Cardiol. 2006, 97, 1287–1291. [Google Scholar] [CrossRef]
- Geiser, F.; Meier, C.; Wegener, I.; Imbierowicz, K.; Conrad, R.; Liedtke, R.; Oldenburg, J.; Harbrecht, U. Association between anxiety and factors of coagulation and fibrinolysis. Psychother. Psychosom. 2008, 77, 377–383. [Google Scholar] [CrossRef] [PubMed]
- Stergiou, G.S.; Palatini, P.; Parati, G.; O’Brien, E.; Januszewicz, A.; Lurbe, E.; Persu, A.; Mancia, G.; Kreutz, R. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J. Hypertens. 2021, 39, 1293–1302. [Google Scholar] [CrossRef] [PubMed]
- Atkinson, G.; Batterham, A.M. Allometric scaling of diameter change in the original flow-mediated dilation protocol. Atherosclerosis 2013, 226, 425–427. [Google Scholar] [CrossRef] [PubMed]
- Kayikcioglu, O.; Bilgin, S.; Seymenoglu, G.; Deveci, A. State and Trait Anxiety Scores of Patients Receiving Intravitreal Injections. Biomed. Hub. 2017, 2, 1–5. [Google Scholar] [CrossRef]
- Lugo-Gavidia, L.M.; Burger, D.; Bosio, E.; Robinson, S.; Nolde, J.; Carnagarin, R.; Matthews, V.B.; Schlaich, M.P. A standarized protocol for evaluation of large extracellular vesicles using the attune™ NXT system. J. Immunol. Methods 2021, 499, 113170. [Google Scholar] [CrossRef]
Study Population n = 62 | |
---|---|
Male | 40 (64.5%) |
Age | 53.9 (15.2) |
BMI (Kg/m2) | 29.3 (5.08) |
Diabetes | 19 (30.6%) |
Hypertension | 52 (83.9%) |
Dyslipidaemia | 36 (58.1%) |
White cell count (10*9/L) | 6.11 (1.56) |
Red cell count (10*9/L) | 4.81 (0.440) |
Haematocrit (L/L) | 0.43 (0.03) |
Haemoglobin (g/L) | 143 (11.1) |
Platelet count (10*9/L) | 248 (56.7) |
Glucose (mmol/L) | 5.95 (1.47) |
HbA1c (%) | 6.15 (1.16) |
Total cholesterol (mmol/L) | 4.90 (1.14) |
Triglyceride (mmol/L) | 1.61 (1.14) |
HDL-cholesterol (mmol/L) | 1.26 (0.306) |
LDL-cholesterol (mmol/L) | 2.93 (0.917) |
Creatinine (umol/L) | 76.3 (19.1) |
eGFR (ml/min/1.73 m2) | 84.0 (11.9) |
UACR (ug/mg) | 1.43 (1.61) |
Sys AOBP (mmHg) | 128 (14.8) |
Dia AOBP (mmHg) | 77.3 (12.1) |
ABPM 24 h-SBP (mmHg) | 133 (15.0) |
ABPM 24 h-DBP (mmHg) | 77.3 (11.8) |
ABPM Day-SBP (mmHg) | 135 (15.6) |
ABPM Day-DBP (mmHg) | 79.4 (12.4) |
ABPM Night-SBP (mmHg) | 121 (16.8) |
ABPM Night-DBP (mmHg) | 68.7 (10.8) |
Hypertensive | Normotensive | p | |
---|---|---|---|
(n = 52) | (n = 10) | ||
Whole superficial vascular plexus density | 46.0 (3.01) | 46.9 (2.62) | 0.37 |
Fovea superficial vascular plexus density | 21.0 (4.98) | 18.9 (6.39) | 0.35 |
Parafovea superficial vascular plexus density | 48.8 (3.31) | 50.0 (2.61) | 0.23 |
Whole deep vascular plexus density | 51.3 (3.45) | 52.5 (1.93) | 0.15 |
Fovea deep vascular plexus density | 36.4 (5.93) | 34.4 (7.45) | 0.43 |
Parafovea deep vascular plexus density | 52.9 (3.52) | 54.2 (2.25) | 0.14 |
Retinal thickness | 318 (17.4) | 316 (22.0) | 0.16 |
UACR (ug/mg) | 1.43 (1.62) | 1.43 (1.69) | 0.99 |
PWV (m/s) | 8.36 (1.52) | 5.77 (1.35) | <0.001 |
Mean arterial pressure (mmHg) | 96.6 (10.8) | 84.0 (10.4) | <0.01 |
Aortic augmentation pressure (mmHg) | 9.59 (5.20) | 6.50 (8.55) | 0.30 |
Augmentation index (%) | 19.3 (12.1) | 6.60 (17.5) | 0.05 |
pEV Concentration (pEV/uL) | 10.4 (6.70) | 6.34 (4.43) | 0.03 |
FMD | EndoPAT * | |||||
---|---|---|---|---|---|---|
Endothelial Dysfunction (n = 23) | No Endothelial Dysfunction (n = 16) | p-Value | Endothelial Dysfunction (n = 9) | No Endothelial Dysfunction (n = 29) | p-Value | |
Sys AOBP (mmHg) | 130 (14.0) | 132 (15.3) | 0.71 | 123 (10.9) | 133 (14.8) | 0.07 |
Dia AOBP (mmHg) | 78.3 (9.88) | 77.4 (12.5) | 0.80 | 80.9 (7.74) | 76.5 (11.4) | 0.29 |
ABPM 24 h-SBP (mmHg) | 134 (10.6) | 133 (16.0) | 0.90 | 135 (18.9) | 133 (11.0) | 0.71 |
ABPM 24 h-DBP (mmHg) | 78.0 (9.80) | 73.1 (10.3) | 0.14 | 76.6 (8.26) | 75.1 (10.3) | 0.70 |
ABPM Day-SBP (mmHg) | 136 (9.80) | 133 (17.4) | 0.53 | 133 (20.0) | 136 (11.0) | 0.57 |
ABPM Day-DBP (mmHg) | 80.0 (10.2) | 75.4 (11.1) | 0.19 | 78.4 (9.22) | 77.2 (10.7) | 0.76 |
ABPM Night-SBP (mmHg) | 123 (18.7) | 117 (11.4) | 0.28 | 118 (12.0) | 120 (17.3) | 0.69 |
ABPM Night-DBP (mmHg) | 68.3 (10.4) | 62.4 (9.97) | 0.09 | 65.8 (8.88) | 65.3 (10.8) | 0.92 |
pEV Concentration (pEV/uL) | 8.51 (5.52) | 11.2 (6.74) | 0.17 | 11.1 (8.85) | 9.32 (5.17) | 0.45 |
Low | Moderate | High | p-Value | |
---|---|---|---|---|
Anxiety category (Trait) | (n = 32) | (n = 9) | (n = 8) | |
Sys AOBP (mmHg) | 132 (15.8) | 136 (15.4) | 123 (13.4) | 0.17 |
Dia AOBP (mmHg) | 77.3 (12.1) | 81.2 (16.1) | 79.9 (8.81) | 0.66 |
ABPM 24 h-SBP (mmHg) | 136 (12.2) | 132 (15.3) | 130 (12.4) | 0.36 |
ABPM 24 h-DBP (mmHg) | 76.8 (10.7) | 77.1 (11.3) | 80.1 (9.89) | 0.73 |
ABPM Day-SBP (mmHg) | 138 (13.3) | 136 (17.5) | 134 (11.5) | 0.71 |
ABPM Day-DBP (mmHg) | 79.0 (11.4) | 79.6 (13.0) | 83.3 (9.88) | 0.65 |
ABPM Night-SBP (mmHg) | 124 (16.6) | 116 (10.4) | 109 (11.0) | 0.04 |
ABPM Night-DBP (mmHg) | 67.2 (11.0) | 66.1 (8.15) | 64.4 (9.14) | 0.80 |
Cortisol | 282 (96.7) | 354 (85.6) | 228 (46.7) | 0.08 |
hsCRP | 2.97 (4.55) | 2.95 (3.11) | 5.97 (12.8) | 0.52 |
pEV Concentration (pEV/uL) | 9.70 (6.59) | 8.62 (3.61) | 9.46 (4.80) | 0.89 |
Anxiety category (State) | (n = 37) | (n = 6) | (n = 6) | |
Sys AOBP (mmHg) | 132 (16.3) | 133 (16.1) | 128 (12.4) | 0.83 |
Dia AOBP (mmHg) | 78.8 (12.4) | 74.3 (14.3) | 80.0 (11.2) | 0.68 |
ABPM 24 h-SBP (mmHg) | 135 (13.3) | 132 (7.76) | 136 (15.4) | 0.85 |
ABPM 24 h-DBP (mmHg) | 77.6 (10.2) | 70.8 (12.4) | 82.8 (9.02) | 0.14 |
ABPM Day-SBP (mmHg) | 137 (14.6) | 137 (9.70) | 138 (13.1) | 0.96 |
ABPM Day-DBP (mmHg) | 79.8 (11.2) | 74.3 (14.6) | 85.3 (7.74) | 0.25 |
ABPM Night-SBP (mmHg) | 122 (15.1) | 111 (6.06) | 122 (26.1) | 0.33 |
ABPM Night-DBP (mmHg) | 67.6 (9.49) | 57.5 (7.77) | 70.0 (13.2) | 0.05 |
Cortisol | 288 (90.7) | 295 (118) | 220 (65.6) | 0.48 |
hsCRP | 2.96 (4.51) | 7.47 (13.5) | 1.76 (0.766) | 0.22 |
EV Concentration (cEV/uL) | 9.08 (6.18) | 8.04 (3.58) | 13.3 (3.94) | 0.21 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lugo-Gavidia, L.M.; Burger, D.; Nolde, J.M.; Matthews, V.B.; Schlaich, M.P. Evaluation of Circulating Platelet Extracellular Vesicles and Hypertension Mediated Organ Damage. Int. J. Mol. Sci. 2022, 23, 15150. https://doi.org/10.3390/ijms232315150
Lugo-Gavidia LM, Burger D, Nolde JM, Matthews VB, Schlaich MP. Evaluation of Circulating Platelet Extracellular Vesicles and Hypertension Mediated Organ Damage. International Journal of Molecular Sciences. 2022; 23(23):15150. https://doi.org/10.3390/ijms232315150
Chicago/Turabian StyleLugo-Gavidia, Leslie Marisol, Dylan Burger, Janis M. Nolde, Vance B. Matthews, and Markus P. Schlaich. 2022. "Evaluation of Circulating Platelet Extracellular Vesicles and Hypertension Mediated Organ Damage" International Journal of Molecular Sciences 23, no. 23: 15150. https://doi.org/10.3390/ijms232315150